Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US
MT newswire2026/09/17 11:54Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
07:54 AM EDT, 09/17/2026 (MT Newswires) -- Kamada (KMDA) confirmed that it maintains "sufficient" supply and manufacturing capacity for its KedRAB anti-rabies immunoglobulin product to meet increasing demand in the US, the company said Thursday. The confirmation follows the US Centers for Disease Control and Prevention's recent advisory on the "significant" increase in human rabies exposures and subsequent use of rabies post-exposure prophylaxis, the company said.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Generac Holdings Up Over 23%, on Pace for Largest Percent Increase Since May 2012 -- Data Talk
Dow Jones•2026/09/17 13:40
Intuit Reiterates Fiscal Q1, Fiscal 2027 Guidance
MT newswire•2026/09/17 13:35
India Buys Record $15.2B in U.S. Treasuries on RBI-Driven Dollar Inflows
CoinEdition•2026/09/17 13:30
Sector Update: Financial Stocks Rise Premarket Thursday
MT newswire•2026/09/17 13:19
